Bartkova Jirina, Tommiska Johanna, Oplustilova Lenka, Aaltonen Kirsimari, Tamminen Anitta, Heikkinen Tuomas, Mistrik Martin, Aittomäki Kristiina, Blomqvist Carl, Heikkilä Päivi, Lukas Jiri, Nevanlinna Heli, Bartek Jiri
Institute Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Copenhagen, Denmark.
Mol Oncol. 2008 Dec;2(4):296-316. doi: 10.1016/j.molonc.2008.09.007. Epub 2008 Oct 7.
The MRE11, RAD50, and NBS1 genes encode proteins of the MRE11-RAD50-NBS1 (MRN) complex critical for proper maintenance of genomic integrity and tumour suppression; however, the extent and impact of their cancer-predisposing defects, and potential clinical value remain to be determined. Here, we report that among a large series of approximately 1000 breast carcinomas, around 3%, 7% and 10% tumours showed aberrantly reduced protein expression for RAD50, MRE11 and NBS1, respectively. Such defects were more frequent among the ER/PR/ERBB2 triple-negative and higher-grade tumours, among familial (especially BRCA1/BRCA2-associated) rather than sporadic cases, and the NBS1 defects correlated with shorter patients' survival. The BRCA1-associated and ER/PR/ERBB2 triple-negative tumours also showed high incidence of constitutively active DNA damage signalling (gammaH2AX) and p53 aberrations. Sequencing the RAD50, MRE11 and NBS1 genes of 8 patients from non-BRCA1/2 breast cancer families whose tumours showed concomitant reduction/loss of all three MRN-complex proteins revealed two germline mutations in MRE11: a missense mutation R202G and a truncating mutation R633STOP (R633X). Gene transfer and protein analysis of cell culture models with mutant MRE11 implicated various destabilization patterns among the MRN complex proteins including NBS1, the abundance of which was restored by re-expression of wild-type MRE11. We propose that germline mutations qualify MRE11 as a novel candidate breast cancer susceptibility gene in a subset of non-BRCA1/2 families. Our data have implications for the concept of the DNA damage response as an intrinsic anti-cancer barrier, various components of which become inactivated during cancer progression and also represent the bulk of breast cancer susceptibility genes discovered to date.
MRE11、RAD50和NBS1基因编码MRE11-RAD50-NBS1(MRN)复合物的蛋白质,该复合物对基因组完整性的正常维持和肿瘤抑制至关重要;然而,它们的癌症易感性缺陷的程度和影响以及潜在的临床价值仍有待确定。在此,我们报告在一大系列约1000例乳腺癌中,分别约有3%、7%和10%的肿瘤显示RAD50、MRE11和NBS1的蛋白表达异常降低。这些缺陷在ER/PR/ERBB2三阴性和高级别肿瘤中更常见,在家族性(尤其是BRCA1/BRCA2相关)而非散发性病例中更常见,并且NBS1缺陷与患者较短的生存期相关。BRCA1相关和ER/PR/ERBB2三阴性肿瘤还显示出持续激活的DNA损伤信号(γH2AX)和p53畸变的高发生率。对来自非BRCA1/2乳腺癌家族的8例患者的肿瘤显示所有三种MRN复合物蛋白同时减少/缺失的RAD50、MRE11和NBS1基因进行测序,发现MRE11中有两个种系突变:一个错义突变R202G和一个截短突变R633STOP(R633X)。对具有突变MRE11的细胞培养模型进行基因转移和蛋白质分析,发现MRN复合物蛋白(包括NBS1)之间存在各种不稳定模式,野生型MRE11的重新表达可恢复其丰度。我们提出种系突变使MRE11成为非BRCA1/2家族亚群中的一种新型候选乳腺癌易感基因。我们的数据对DNA损伤反应作为一种内在抗癌屏障的概念具有启示意义,其中各种成分在癌症进展过程中失活,并且也代表了迄今为止发现的大多数乳腺癌易感基因。